A person goes shopping on Tuesday. Wednesday is manageable. On Thursday, standing to make breakfast feels impossible. For someone with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), the problem may not be the shopping itself but the delayed, disproportionate deterioration that follows it. That delay is central to understanding the disease, and to avoiding advice that can make it worse.

In brief: ME/CFS is a disabling, multisystem illness characterised by reduced function, unrefreshing sleep and post-exertional malaise (PEM): symptoms that worsen after physical, cognitive or emotional exertion. The cause is not established, no single test confirms it, and there is no proven cure. This article explains what can be measured, what remains uncertain and how current CDC and NICE guidance approaches care.

The distinguishing feature. PEM is not ordinary tiredness after effort. The deterioration can start 12–48 hours later and last days or weeks. Advice to increase activity on a fixed timetable can worsen the illness.

ME/CFS is more than persistent fatigue

The word fatigue covers everything from a poor night’s sleep to severe disease. ME/CFS involves a characteristic loss of physical and cognitive capacity. A shower, a meeting, a short walk or concentration on a document can consume more energy than a person can reliably recover from. Sleep often fails to restore that capacity.

This is not a rare complaint masquerading as a diagnosis. In the US National Health Interview Survey for 2021–2022, 1.3% of adults reported having been told by a healthcare professional that they had ME/CFS. That figure is a survey estimate based on reported diagnosis, not a biomarker-validated count. It does not tell us how many people have the condition without a diagnosis or whether every reported diagnosis meets a single research definition.

The delayed crash: what post-exertional malaise means

In healthy recovery, a demanding activity may leave someone tired or sore before capacity returns. In PEM, an amount of exertion that looks modest can trigger a disproportionate flare of symptoms: profound exhaustion, pain, sensory sensitivity, difficulty thinking, disturbed sleep, flu-like symptoms, dizziness or an inability to remain upright.

According to the CDC clinical guidance, the deterioration typically appears 12–48 hours after activity and may last days or weeks. The exertion need not be exercise. Conversation, studying, emotional stress and sitting upright for long periods may count.

The timing creates a diagnostic trap. A patient may appear to have tolerated a clinic visit or workout and deteriorate only the following day. A clinician who judges the intervention by how the patient felt immediately afterwards can miss the cost.

A practical question with more diagnostic value than ‘Are you tired?’

What happened the next day and the day after your last demanding activity? Could you do the same amount again? How long did it take to recover? These questions do not independently diagnose ME/CFS, but they expose the pattern that generic fatigue questionnaires often miss.

How ME/CFS is diagnosed without one definitive laboratory test

The CDC diagnostic approach looks for a substantial, persistent decline in previous functioning with fatigue, PEM, unrefreshing sleep, and at least one of cognitive impairment or orthostatic intolerance. In the US approach discussed by CDC, the symptom pattern persists for six months or longer. Other clinical guidance, including NICE in the UK, uses different timing thresholds. Those differences reflect criteria, not evidence that the disease suddenly begins on a particular calendar day.

Clinicians also evaluate other explanations that can coexist with or resemble ME/CFS, such as anaemia, thyroid disease, medication effects, sleep disorders, autoimmune illness and some mental-health conditions. A careful work-up protects patients from both errors: dismissing ME/CFS and overlooking a treatable additional illness.

No validated blood-test panel rules ME/CFS in or out. Research has reported abnormalities in immune signalling, autonomic function, energy metabolism and other systems, but no current marker has adequate sensitivity and specificity for routine confirmation. A normal standard blood test therefore does not prove the patient’s symptoms are imaginary.

Can exertional intolerance be measured objectively?

A particularly informative research approach compares cardiopulmonary exercise testing on two consecutive days. Instead of looking only at maximal performance on one occasion, it asks whether physiological performance can be reproduced after roughly 24 hours.

In a 2024 study of 84 people with ME/CFS and 71 sedentary controls, the ME/CFS group showed reductions on the second test in several measures, including peak oxygen consumption and workload, that were not seen in the same pattern among controls. It supports the proposition that exertional impairment can have an objective physiological signature in some studied patients.

But the study was not a population diagnostic-validation experiment. Participants were selected, the protocol imposes heavy exertion, results may differ by disease severity and alternative explanations must be considered. Two-day exercise testing can provoke a serious crash; it should not be presented as a routine self-test or required proof of illness. There is a large distance between an interesting group-level signal and a safe individual diagnostic test.

How to read a scientific claim. An abnormal result in a carefully selected patient group can support a biological mechanism without becoming a reliable screening test for everyone with fatigue. The two claims require different evidence.

Pacing is not the same as giving up on movement

The central management problem is not how to force a fixed increase in activity but how to prevent cycles of exertion and relapse. Pacing means identifying an individual’s variable physical, mental and social energy limits, spreading essential tasks over time and building rest into plans before a crash occurs.

The energy envelope is not a precise measurable tank, and pacing is not a proven cure. It is a practical strategy for reducing symptom exacerbation. Severe patients may have very narrow limits, including for basic personal care. A routine suitable for one individual can be excessive for another.

NICE’s NG206 guideline explicitly advises against programmes with fixed incremental increases in activity, sometimes termed graded exercise therapy, and against using exercise as a cure. The guideline does not forbid every movement or every carefully individualised rehabilitation intervention. If a patient chooses activity work, NICE calls for an ME/CFS specialist team’s oversight, a baseline that does not worsen symptoms and flexible adjustments according to response.

A symptom and activity diary can help reveal delays. It should never become another exhausting administrative task. Short notes such as ‘Tuesday: appointment; Thursday: flare; Saturday: improving’ may be more useful than an elaborate tracking spreadsheet.

Orthostatic intolerance: when being upright is itself exertion

For some patients, standing in a queue, showering or sitting upright produces dizziness, palpitations, blurred vision or cognitive deterioration. This is orthostatic intolerance, which can coexist with postural orthostatic tachycardia syndrome (POTS) or abnormal blood-pressure responses.

Clinical evaluation may include heart rate and blood pressure while lying down and standing, or referral for specialised autonomic testing. Not every patient with ME/CFS has POTS, and dizziness alone does not establish either diagnosis.

Treatment can include reducing prolonged standing, adjusting daily activities and, for selected patients, compression, fluids, salt or medication under professional supervision. Salt and fluid loading are not universally safe, especially with kidney or heart disease or hypertension. The important point is to identify a tractable contributor rather than treating every symptom as an unsolvable part of fatigue.

Treatment: target the most disabling symptoms, without pretending to cure the disease

As of October 2026, there is no broadly validated curative medicine or universally effective treatment for ME/CFS. Care generally focuses on reducing crashes and addressing treatable contributors to sleep disturbance, pain, headache, gastrointestinal symptoms, orthostatic intolerance and coexisting conditions.

Psychological support may help someone cope with disability, loss of work, uncertainty and strain on relationships. That is not evidence that unresolved emotions cause ME/CFS. The earlier version of this article blurred this boundary by borrowing claims from motivational and self-help writing. Those claims have been removed.

What about long COVID?

Some people with long COVID develop PEM, orthostatic symptoms and cognitive impairment that overlap with ME/CFS; some meet ME/CFS criteria. Others have different post-COVID symptoms and mechanisms. The categories therefore overlap but should not be treated as synonyms. This is an active research area, and it does not justify assuming that one laboratory finding or treatment will apply to both populations.

A short, useful checklist before a medical appointment

  • Describe the change: What could you do before illness that you cannot reliably do now?
  • Describe the lag: What happens 12, 24 and 48 hours after physical or cognitive exertion?
  • Describe recovery: How long does a flare last, and what activity preceded it?
  • Describe upright symptoms: Any dizziness, palpitations, faintness, heat intolerance or need to lie down?
  • Review alternatives: Sleep quality, medications, infections, mood changes and conditions already investigated.
  • Ask about safety: How can investigations and appointments be arranged without provoking a prolonged deterioration?

This is a conversation aid, not a diagnostic score. Sudden or severe chest pain, fainting, new neurological deficits or serious breathlessness require prompt medical assessment rather than attribution to ME/CFS.

What science still needs to resolve

Why is recovery from an ordinary demand abnormal in some people? Are the key mechanisms primarily autonomic, immune, vascular, metabolic, neurological, or different in distinct patient subgroups? Can an accessible, reproducible test detect the illness without making people worse? Most importantly, can a treatment be shown in controlled studies to restore functioning rather than merely move a biomarker?

These are better questions than whether patients are sufficiently motivated. Where strong biological observations conflict with an oversimplified theory of deconditioning, the theory needs revision; where a proposed biomarker fails independent replication, that biomarker needs revision too.

Bottom line

ME/CFS is defined neither by ordinary tiredness nor by a patient’s attitude. The striking feature is disproportionate, often delayed deterioration after exertion. Current evidence supports careful clinical assessment, avoidance of fixed activity escalation and individualised management of disabling symptoms. Research can measure some abnormalities, but none yet supplies a universally safe, definitive test or cure.

Primary sources